Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

RGT-61159

Stage Phase 1

Sponsor Rgenta Therapeutics

Route oral, once daily

Class MYB splicing modulator

Mechanism oral small molecule that shifts MYB splicing to reduce MYB

Target MYB (MYB-NFIB)

Sources

company_release, as of 2026-11-07

https://www.globenewswire.com/news-release/2026/10/22/3386297/0/en/rgenta-therapeutics-announces-successful-end-of-phase-2-meeting-with-fda-and-alignment-on-phase-3-trial-design-for-rgt-61159-in-patients-with-adenoid-cystic-carcinoma-acc.html

Rgenta Therapeutics release, 10.22.2026 (company release; opened 2026-10-27): end-of-Phase 2 meeting with FDA, alignment on Phase 3 of RGT-61159 in ACC; planned start 1Q 2027; double-blind, placebo-controlled, about 150 biomarker-selected patients, randomized 2:2:1 to 84 mg, 60 mg or placebo once daily, all with best supportive care; primary endpoint PFS; key secondary OS, safety, tolerability; North America and Europe. Phase 1a/b: disease control 84.6% (33 of 39) at or below RP2D, 3 partial responses. About 200,000 people live with ACC worldwide and 11,000 in the US (company figure).

Brief source A8

company_release, as of 2026-11-07

https://www.globenewswire.com/news-release/2026/05/21/3299781/0/en/rgenta-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-1a-b-clinical-trial-of-rgt-61159-in-patients-with-adenoid-cystic-carcinoma-and-colorectal-cancer-at-the-20.html

Rgenta Therapeutics release, 05.21.2026 (company release; opened 2026-10-27), ASCO 2026 abstract 3089 (doi 10.1200/jco.2026.44.16_suppl.3089; abstract not opened): 39 evaluable patients at or below RP2D, disease control 84.6% (33), 3 partial responses (2 confirmed, 1 pending confirmation); partial responders on study a mean 8.2 months; most common adverse events fatigue, anemia, diarrhea, nausea. Preliminary. The release gives no grade 3 or discontinuation rates; a grade 3 vasculitis at 144 mg noted in a search record of the abstract is not verified.

Brief source A10

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06462183

A Phase 1a/1b, First-in-human, Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

RGT-61159 Phase 1a/b

Registry NCT06462183

Phase Phase 1

Status Active, not recruiting

Enrollment 105

Start 2024-08-19

Primary completion 2027-12

Study completion 2027-12

Catalyst Primary completion. 12.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

RGT-61159 at or below RP2D

Dose at or below RP2D (mixed doses)

Regimen once daily

Population R/R ACC, evaluable (n = 39)

Estimand Single arm

disease control rate: 84.6%, ASCO 2026, preliminary

partial responses: 3 patients (of 39), ASCO 2026; 2 confirmed, 1 pending

RGT-61159 Phase 3 (planned, not yet registered)

Phase Phase 3

Status Not yet recruiting

Enrollment 150

Catalyst Phase 3 start (company plan). Q1 2027. Company release 10.22.2026: start planned 1Q 2027.

RGT-61159 84 mg + best supportive care

Dose 84 mg

Regimen once daily

Comparator placebo

Population biomarker-selected R/M ACC (about 150 total, 2:2:1)

Estimand ITT

RGT-61159 60 mg + best supportive care

Dose 60 mg

Regimen once daily

Comparator placebo

Population biomarker-selected R/M ACC

Estimand ITT

Placebo + best supportive care

Dose placebo

Regimen once daily

Population biomarker-selected R/M ACC

Estimand ITT